These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17012871)

  • 21. Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine.
    Bayliss J; Nissen M; Prakash D; Richmond P; Oh KB; Nolan T
    Hum Vaccin Immunother; 2021 Jan; 17(1):176-190. PubMed ID: 32573398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants.
    Tanaka Y; Yokokawa R; Rong HS; Kishino H; Stek JE; Nelson M; Lawrence J
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-7. PubMed ID: 28140752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study.
    Zhu Y; Sun L; Wang Y; Wang J; Wang Y; Li J; Wang L; Guo Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2372884. PubMed ID: 38957938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.
    Aloysia D'Cor N; Siddaiah P; Mohapatra S; Dhaded SM; I V P; Kar S; V N T; Muley P; Chhatwal J; Patnaik BN; Vidor E; Moureau A; Patel DM; Midde VJ; Jagga SR; Peesapati S; Noriega F
    PLoS One; 2023; 18(8):e0284898. PubMed ID: 37582114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B and pertussis antibodies in 4- to 5-year-old children previously vaccinated with different hexavalent vaccines.
    Vesikari T; Xu J; Johnson DR; Hall J; Marček T; Goveia MG; Acosta CJ; Lee AW
    Hum Vaccin Immunother; 2020 Apr; 16(4):867-874. PubMed ID: 31689166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postmarketing Safety Surveillance of a Hexavalent Vaccine in the Vaccine Adverse Event Reporting System.
    Moro PL; Zhang B; Marquez P; Reich J
    J Pediatr; 2023 Nov; 262():113643. PubMed ID: 37517652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age.
    Gold R; Barreto L; Ferro S; Thippawong J; Guasparini R; Meekison W; Russell M; Mills E; Harrison D; Lavigne P
    Can J Infect Dis Med Microbiol; 2007 Jul; 18(4):241-8. PubMed ID: 18923741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.
    O'Connor D; Pinto MV; Sheerin D; Tomic A; Drury RE; Channon-Wells S; Galal U; Dold C; Robinson H; Kerridge S; Plested E; Hughes H; Stockdale L; Sadarangani M; Snape MD; Rollier CS; Levin M; Pollard AJ
    Mol Syst Biol; 2020 Nov; 16(11):e9888. PubMed ID: 33210468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of a Haemophilus influenzae type b conjugate vaccine process intended for technology transfer.
    Hamidi A; Verdijk P; Kreeftenberg H
    Hum Vaccin Immunother; 2014; 10(9):2691-6. PubMed ID: 25483504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial.
    Grassly NC; Andrews N; Cooper G; Stephens L; Waight P; Jones CE; Heath PT; Calvert A; Southern J; Martin J; Miller E
    Vaccine; 2023 Feb; 41(7):1299-1302. PubMed ID: 36690561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed drug eruption after pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and
    Savaş Erdoğan S; Cebeci Kahraman F
    Eur J Hosp Pharm; 2023 Jul; 30(4):e16. PubMed ID: 34233904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure.
    Boisnard F; Manson C; Serradell L; Macina D
    Expert Rev Vaccines; 2023; 22(1):1196-1213. PubMed ID: 37936265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-administration of routine paediatric vaccines in England often deviates from the immunisation schedule.
    Bauwens J; de Lusignan S; Sherlock J; Ferreira F; Künzli N; Bonhoeffer J
    Vaccine X; 2021 Dec; 9():100115. PubMed ID: 34622200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine.
    Olivera I; Grau C; Dibarboure H; Torres JP; Mieres G; Lazarov L; Alvarez FP; Yescas JGL
    BMC Health Serv Res; 2020 Apr; 20(1):295. PubMed ID: 32272920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rejoinder to comments on ''Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China''.
    Amimo F
    Hum Vaccin Immunother; 2024 Dec; 20(1):2375668. PubMed ID: 39024500
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.
    Abdulla S; Salim N; Machera F; Kamata R; Juma O; Shomari M; Kubhoja S; Mohammed A; Mwangoka G; Aebi T; Mshinda H; Schellenberg D; Carter T; Villafana T; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
    Malar J; 2013 Jan; 12():11. PubMed ID: 23297680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost minimization analysis of a hexavalent vaccine in Argentina.
    Olivera I; Pérez CG; Lazarov L; Lopez E; Oddo C; Dibarboure H
    BMC Health Serv Res; 2023 Oct; 23(1):1067. PubMed ID: 37803345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of immuno assays during the development of a Hemophilus influenzae type b vaccine for technology transfer to emerging vaccine manufacturers.
    Hamidi A; Kreeftenberg H
    Hum Vaccin Immunother; 2014; 10(9):2697-703. PubMed ID: 25483494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and factors associated with pentavalent vaccination: a cross-sectional study in Southern China.
    Xu J; Cui Y; Huang C; Dong Y; Zhang Y; Fan L; Li G; Jiang F
    Infect Dis Poverty; 2023 Sep; 12(1):84. PubMed ID: 37715293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China.
    Huang A; Xu X; Tang L; Huang L; Li J; Zhang X; Liu J; Zhou Y; Zhang B; Wang L; Zhang Q; Zhou Z; Wang Y; Wang X; Liu Q; Liu S; Yin Z; Wang F
    Hum Vaccin Immunother; 2024 Dec; 20(1):2333098. PubMed ID: 38619056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.